Published in Bone on October 12, 2016
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem (2007) 4.74
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem (2006) 3.10
Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest (2005) 3.00
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med (2011) 2.34
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A (2015) 2.25
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet (2002) 2.21
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res (2012) 2.18
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One (2011) 2.10
Pathogenesis of myeloma bone disease. Leukemia (2008) 2.04
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem (2003) 1.86
BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development (2008) 1.86
Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A (2012) 1.78
The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. Bone Miner (1987) 1.77
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med (2016) 1.75
Function of osteocytes in bone. J Cell Biochem (1994) 1.74
Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res (2007) 1.74
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res (2011) 1.72
Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol (2011) 1.70
Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One (2009) 1.67
Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res (2001) 1.64
Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem (2011) 1.63
Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res (2014) 1.49
Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab (2011) 1.46
The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem (2009) 1.41
The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One (2011) 1.40
Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci (2010) 1.37
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J Bone Miner Res (2012) 1.28
Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem (2013) 1.23
Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet (1999) 1.23
Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest (2010) 1.18
Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem (2010) 1.17
Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum (2013) 1.12
High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res (2012) 1.12
Sclerostin in mineralized matrices and van Buchem disease. J Dent Res (2009) 1.11
Two cases of Van Buchem's disease. J Neurol Neurosurg Psychiatry (1982) 1.11
Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology (2011) 1.11
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol (2013) 1.10
Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia (2013) 1.05
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res (2011) 1.05
Dissecting the hematopoietic microenvironment. VIII. Clonal isolation and identification of cell types in murine CFU-F colonies by limiting dilution. Exp Hematol (1990) 1.04
Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett (2011) 1.04
Effects of PTH on osteocyte function. Bone (2012) 1.03
Oxygen tension differentially influences osteogenic differentiation of human adipose stem cells in 2D and 3D cultures. J Cell Biochem (2010) 1.03
Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone (2013) 1.02
Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology (2011) 1.02
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer (2011) 1.01
Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol (2013) 1.00
Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem (2008) 0.99
Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum (2011) 0.99
Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J (2011) 0.99
Sclerostin is a direct target of osteoblast-specific transcription factor osterix. Biochem Biophys Res Commun (2010) 0.98
Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women. J Clin Endocrinol Metab (2012) 0.98
Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res (2009) 0.97
Clinical utility of serum sclerostin measurements. Bonekey Rep (2013) 0.96
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density. J Bone Miner Res (2015) 0.95
TGF-β regulates sclerostin expression via the ECR5 enhancer. Bone (2011) 0.94
Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci (2011) 0.94
Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem (2013) 0.94
Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One (2015) 0.93
The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro. J Biol Chem (2015) 0.93
Sclerostin Inhibition in the Management of Osteoporosis. Calcif Tissue Int (2016) 0.92
Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology (2014) 0.92
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res (2016) 0.91
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun (2015) 0.89
Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem (2013) 0.88
The sclerostin-bone protein interactome. Biochem Biophys Res Commun (2011) 0.87
Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis (2013) 0.87
New insights into the location and form of sclerostin. Biochem Biophys Res Commun (2014) 0.86
Osteocyte deficiency in hip fractures. Calcif Tissue Int (2011) 0.84
Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet (2011) 0.84
Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol (2014) 0.84
Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation. J Biol Chem (2014) 0.83
Measurement of caspase activity in cells undergoing apoptosis. Methods Mol Biol (2004) 0.83